U.S. pharma big copyright scrapped two experimental weight loss products last 12 months—a at the time-day-to-day tablet, lotiglipron, as a consequence of elevated liver enzymes along with a 2 times-every day capsule, danuglipron, as a consequence of robust Uncomfortable side effects—but CEO Albert Bourla has claimed the company is decided to �